Study #2022-0938
A phase 1 study of JV-213 autologous CD79b-targeting chimeric antigen receptor T-cell therapy in adults with relapsed or refractory B-cell lymphomas
MD Anderson Study Status
Enrolling
Treatment Agent
JV-213
Description
To find the highest tolerable dose of JV-213 (a type of autologous CAR T cell therapy) that can be given to patients who have B-cell lymphoma that is relapsed or refractory.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Lymphomas, B-cell Lymphomas
Study phase:
Phase I
Physician name:
Sattva Neelapu
Department:
Lymphoma/Myeloma
For general questions about clinical trials:
1-844-737-0154
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.